Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study

Huneck Haupt, Thomas; Petersen, Janne; Ellwkilde, Gertrude; Hedegaard Klausen, Henrik; Wandall Thorball, Christian; Eugen-Olsen, Jesper; Andersen, Ove
July 2012
Critical Care;2012, Vol. 16 Issue 4, p11434
Abstract: Introduction: Soluble urokinase plasminogen activator receptor (suPAR) is the soluble form of the membranebound receptor (uPAR) expressed predominantly on various immune cells. Elevated plasma suPAR concentration is associated with increased mortality in various patient groups, and it is speculated that suPAR is a low-grade inflammation marker reflecting on disease severity. The aim of this prospective observational study was to determine if the plasma concentration of suPAR is associated with admission time, re-admission, disease severity/ Charlson Comorbidity Index Score, and mortality. Methods: We included 543 patients with various diseases from a Danish Acute Medical Unit during a two month period. A triage unit ensured that only medical patients were admitted to the Acute Medical Unit. SuPAR was measured on plasma samples drawn upon admission. Patients were followed-up for three months after inclusion by their unique civil registry number and using Danish registries to determine admission times, readmissions, International Classification of Diseases, 10th Edition (ICD-10) diagnoses, and mortality. Statistical analysis was used to determine suPAR's association with these endpoints.Results: Increased suPAR was significantly associated with 90-day mortality (4.87 ng/ml in survivors versus 7.29 ng/ml in non-survivors, P < 0.0001), higher Charlson Score (P < 0.0001), and longer admission time (P < 0.0001), but not with readmissions. The association with mortality remained when adjusting for age, sex, C-reactive protein (CRP), and Charlson Score. Furthermore, among the various Charlson Score disease groups, suPAR was significantly higher in those with diabetes, cancer, cardiovascular disease, and liver disease compared to those without comorbidities. Conclusions: SuPAR is a marker of disease severity, admission time, and risk of mortality in a heterogeneous cohort of patients with a variety of diseases. The independent value of suPAR suggests it could be of value in prognostic algorithms.


Related Articles

  • Prediction of survival in terminally ill cancer patients at the time of terminal cancer diagnosis. Kim, Yu; Kim, Su-Jung; Lee, June; Choi, Won-Suk; Park, Jin; Kim, Hee; Sim, Sung; Lee, Keun-Wook; Lee, Se-Hoon; Kim, Jee; Kim, Dong-Wan; Lee, Jong; Bang, Yung-Jue; Heo, Dae // Journal of Cancer Research & Clinical Oncology;Sep2014, Vol. 140 Issue 9, p1567 

    Purpose: We aimed to investigate the prognostic factors that can predict terminal stage survival (TSS) at the time of terminal cancer diagnosis. Methods: We prospectively evaluated 141 patients immediately after the diagnosis of terminal cancer by their attending oncologists. A total of 32...

  • Procalcitonin Improves the Glasgow Prognostic Score for Outcome Prediction in Emergency Patients with Cancer: A Cohort Study. Rast, Anna Christina; Kutz, Alexander; Felder, Susan; Faessler, Lukas; Steiner, Deborah; Laukemann, Svenja; Haubitz, Sebastian; Huber, Andreas; Buergi, Ulrich; Conca, Antoinette; Reutlinger, Barbara; Mueller, Beat; Bargetzi, Mario; Schuetz, Philipp // Disease Markers;3/15/2015, p1 

    The Glasgow Prognostic Score (GPS) is useful for predicting long-term mortality in cancer patients. Our aim was to validate the GPS in ED patients with different cancer-related urgency and investigate whether biomarkers would improve its accuracy. We followed consecutive medical patients...

  • C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms. Combariza, Juan; Lombana, Milton; Pino, Luis; Arango, Marcos // Supportive Care in Cancer;Apr2015, Vol. 23 Issue 4, p1009 

    Objective: The objective of this study is to assess the prognostic usefulness of the Multinational Association of Supportive Care in Cancer (MASCC) risk score in association with the value of C-reactive protein (CRP) to identify high-risk patients with febrile neutropenia and hematologic...

  • Nutrition and CVD in the Chiropractic Practice. Toohey, Lynn // American Chiropractor;Jan2005, Vol. 27 Issue 1, p34 

    The article discusses about nutritional support in case of heart patients. One of the reasons for this focus is that recent research shows that these heart nutrients also have favorable effects on bone formation, which is something of interest to every chiropractor. New and important markers now...

  • EXPERIENCE WITH THE USE OF HUMAN FIBRINOLYSIN. Villavicencio, J. Leonel; Warren, Richard // Angiology;Aug1959 Part 2, Vol. 10 Issue 4, p263 

    1. Experiences with the clinical and experimental administration of plasmin are reported. 2. Of the methods for the assay of plasma fibrinolytic activity which were tested (fibrin plate, euglobulin on fibrin clot, euglobulin on benzoyl arginine methyl ester (BAME), plasma on BAME, and whole...

  • Partial Purification and Characterization of Fibrinolytic Enzymes from Yellow Mealworm. Huang, Ming; Ye, Yun; Chen, Ya; Han, Ya // International Journal of Peptide Research & Therapeutics;Jun2012, Vol. 18 Issue 2, p153 

    Two proteins with fibrinolytic activity were partially purified from yellow mealworm ( Tenebrio molitor) by ammonium sulfate precipitation between 30 and 70% saturation, gel filtration on Sephacryl-S200-HR, ion exchange chromatography on DEAE-Sepharose-FF and metal chelate on Cu-HiTrap-IMAC-FF,...

  • Safety evaluation of a recombinant plasmin derivative lacking kringles 2-5 and rt-PA in a rat model of transient ischemic stroke. Crumrine, R. Christian; Marder, Victor J.; McLeod Taylor, G.; LaManna, Joseph C.; Tsipis, Constantinos P.; Novokhatny, Valery; Scuderi, Philip; Petteway Jr., Stephen R.; Arora, Vikram // Experimental & Translational Stroke Medicine;2012, Vol. 4 Issue 1, p10 

    Background: Tissue type plasminogen activator is the only approved thrombolytic agent for the treatment of ischemic stroke. However, it carries the disadvantage of a 10-fold increase in symptomatic and asymptomatic intracranial hemorrhage. A safer thrombolytic agent may improve patient prognosis...

  • Entering the Era of Non-Basic P1 Site Groups: Discovery of Xarelto (Rivaroxaban). Straub, Alexander; Roehrig, Susanne; Hillisch, Alexander // Current Topics in Medicinal Chemistry;Feb2010, Vol. 10 Issue 3, p257 

    Several clinical candidates have now emerged as a result of an intense search for orally available, antithrombotic factor Xa inhibitors. This review highlights the discovery of Xareltoâ„¢ (Rivaroxaban) starting from an initial tetrahydrophthalimide screening hit. The major breakthrough was...

  • Fibrinolytic Serine Protease Isolation from Bacillus amyloliquefaciens An6 Grown on Mirabilis jalapa Tuber Powders. Agrebi, Rym; Hmidet, Noomen; Hajji, Mohamed; Ktari, Nawrez; Haddar, Anissa; Fakhfakh-Zouari, Nahed; Nasri, Moncef // Applied Biochemistry & Biotechnology;Sep2010, Vol. 162 Issue 1, p75 

    In this study, Mirabilis jalapa tuber powder (MJTP) was used as a new complex organic substrate for the growth and production of fibrinolytic enzymes by a newly isolated Bacillus amyloliquefaciens An6. Maximum protease activity (1,057 U/ml) with casein as a substrate was obtained when the strain...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics